다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
大韓癌韓醫學會誌 = Journal of Korean traditional oncology, v.21 no.1, 2016년, pp.1 - 14
정현정 (대구한의대학교 진단학 교실) , 유화승 (대전대학교 동서암센터)
AI-Helper
The incidence rate of cervical cancer in Korea is still higher than in other developed countries, notwithstanding the national mass screening program. Cervical cancer prognosis is good due to an effective treatment such as surgery or radiation therapy, concurrent chemotherapy in the early stage. How...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
| 핵심어 | 질문 | 논문에서 추출한 답변 |
|---|---|---|
| 자궁경부암의 서양의학적 치료 방법은 무엇이 있는가? | 자궁경부암의 서양의학적 치료는 수술, 항암화학요법, 방사선 요법 그리고 항암화학방사선 동시 요법 등을 크게 구분가능하며, 각 병기에 따른 표준적인 치료 방법을 제시하고 있다. 惡性腫瘤中醫診療指南의 경우 서양의학의 각 치료 시기별로 변증 구분하여 치료방법을 제시하고 있다. | |
| 자궁경부암의 FIGO병기 IA는 어떻게 분류되는가? | 자궁경부 원추절제술은 자궁경부 착공 생검(punch biopsy)으로 침윤 깊이를 알기 힘들거나 미세침윤 여부를 알고자 할 때 권장된다. FIGO병기 IA는 비육안 잠재성 암으로서 IA1은 기질침윤 3.0 mm 미만, IA2는 기질침윤이 3.0 mm 이상, 5.0 mm 미만으로 정의하고 있다. IA1과 IA2 모두 암 침윤의 수평 확산이 7. | |
| 자궁경부암의 원인은 무엇이 있는가? | 자궁경부암의 정확한 원인은 밝혀지지 않았 으나, 조혼, 조기 성교, 다수의 성교 대상자, 성병, 유산 횟수, 출산 경력, 인종이나 사회적 원인 등이 관련된 것으로 알려져 있다3,4). 여러 역학 연구에 의하면 자궁경부암 발생에 가장 중요한 인자는 지속적인 고위험 인유두종바이러스(Human Papillomavirus; HPV) 감염이며, 인유두종바이러스가 만들어 내는 바이러스의 단백질들이 암 발생을 억제하는데 중요한 인체의 종양 억제 유전자로부터 만들어지는 단백질들의 기능을 억제함으로써 암 발생이 유발된다고 알려져 있다5). |
국가암정보센터 http://www.cancer.go.kr/mbs/cancer/subview.jsp?idcancer_040402000000
DeSouza NM, Whittle M, Williams AD, Sohail M, Krausz T, Gilderdale DJ, et al. Magnetic resonance imaging of the primary site in stage I cervical carcinoma: a comparison of endovaginal coil with external phased array coil techniques at 0.5T. J Magn Reson Imaging 2000; 12: 1020-6
Smith AM, Heywood W, Ryall R, Shelley JM, Pitts MK, Richters J, Simpson JM, Patrick K. Association between sexual behavior and cervical cancer screening. J Woman Health (Larchmt) . 2011;20(7): 1091-6
임명철, 이선경, 박성재, 김승보. 자궁경부암 환자의 임상병리학적 분석 및 예후에 관한 연구. 대한산부인과학회지. 2005;48(2):304-13
Kim BJ, Moon G, An Outlook of the Oriental and Western Medical Diagnosis an Treatment on Gastric cnaer. K.O.M.S. 1996:17(2);100-16.
林洪生. 惡性腫瘤中醫診療指南. 북경인민위생출판사. 2014:471-98.
자궁경부암 진료 권고안 ver 2.0 2010
Desouza NM, Dina R, Mcindoe GA, Soutter WP. Cervical cancer: value of an endovaginal coil magnetic resonance imaging technique in detecting small volume disease and assessing parametrial extension. Gynecol Oncol 2006; 102: 80-5
Hricak H, Gatsonis C, Chi DS, Amendola MA, Brandt K, Schwartz LH, et al. Role of imaging in pretreatment evaluation of early invasive cervical cancer: results of the intergroup study American College of Radiology Imaging Network 6651-Gynecologic Oncology Group 183. J Clin Oncol 2005; 23: 9329-37
Elit L, Fyles AW, Devries MC, Oliver TK, Fung-Kee-Fung M; Gynecology Cancer Disease Site Group. Follow-up for women after treatment for cervical cancer: a systematic review. Gynecol Oncol 2009; 114(3): 528-35
鬱仁存, 王笑民. 21世紀中西醫結合腫瘤硏究前瞻. 中醫雜誌. 2001; 42(1): 50-52,
Bansal N, Herzog TJ, Shaw RE, Burke WM, Deutsch I, Wright JD. Primary therapy for early-stage cervical cancer: radical hysterectomy vs radiation. Am J Obstet Gynecol. 2009;201(5):485.e1-9
Koliopoulos G, Sotiriadis A, Kyrgiou M, Martin-Hirsch P, Makrydimas G, Paraskevaidis E. Conservative surgical methods for FIGO stage IA2 squamous cervical carcinoma and their role in preserving women's fertility. Gynecol Oncol 2004; 93(2): 469-73
Bekkers RL, Keyser KG, Bulten J, Hanselaar AG, Schijf CP, Boonstra H, et al. The value of loop electrosurgical conization in the treatment of stage IA1 microinvasive carcinoma of the uterine cervix. Int J Gynecol Cancer 2002; 12(5): 485-9. 12.
Itsukaichi M, Kurata H, Matsushita M, Watanabe M, Sekine M, Aoki Y, et al. Stage Ia1 cervical squamous cell carcinoma: conservative management after laser conization with positive margins. Gynecol Oncol 2003; 90(2): 387-9.
Mota F. Microinvasive squamous carcinoma of the cervix: treatment modalities. Acta Obstet Gynecol Scand 2003; 82(6): 505-9.
Bernardini M, Barrett J, Seaward G, Covens A. Pregnancy outcomes in patients after radical trachelectomy. Am J Obstet Gynecol 2003; 189(5): 1378-82.
Boss EA, van Golde RJ, Beerendonk CC, Massuger LF. Pregnancy after radical trachelectomy: a real option? Gynecol Oncol 2005; 99(3 Suppl 1): S152-6
Chiva LM, Lapuente F, Gonzalez-Cortijo L, Gonzalez-Martin A, Rojo A, Garcia JF, Carballo N. Surgical treatment of recurrent cervical cancer: state of the art and new achievements. Gynecol Oncol 2008; 110(3 Suppl 2): S60-6.
박재갑, 방영주, 하성환. 종양학. 서울 일조각. 2012. 515-543
Martinez-Monge R , Gaztanaga M, Aramendia JM, Cambeiro M, Arbea L, Espinos J, et al. A phase II trial of less than 7 weeks of concomitant cisplatin-paclitaxel chemoradiation in locally advanced cervical cancer. Int J Gynecol Cancer 2010; 20(1): 133-40.
Umayahara K, Takeshima N, Nose T, Fujiwara K, Sugiyama Y, Utsugi K, et al. Phase I study of concurrent chemoradiotherapy with weekly cisplatin and paclitaxel chemotherapy for locally advanced cervical carcinoma in Japanese women. Int J Gynecol Cancer 2009; 19(4): 723-7
Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999; 340(15): 1137-43.
韓磊, 宋艶. 知栢地黃丸的藥理作用和臨床應用硏究進展. 中國藥房. 2012;23(15): 1430-2.
賀西徵, 盧樂萍, 尹富敏. 知栢地黃湯加味治療腫瘤防療毒副反應23例分析. 中醫藥學刊. 2002;20(4):64-6.
李瑞, 陳曾燕. 鍼灸聯合藥物保留灌腸治療宮頸癌？期放射性腸炎的效果觀察. 交通醫學. 2008:22(6):711-2
于玲, 徐蘭 風. 艾葉對宮頸癌放療患子免疫功能的影向. 鍼灸臨床雜誌.2004:20(3):50-2
Thomas GM. Improved treatment for cervical cancer--concurrent chemotherapy and radiotherapy. N Engl J Med 1999; 340(15): 1198-200.
Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CL 3rd, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 1999; 340(15): 1154-61.
Prasad E, Viswanathan PN, Rangad VF, Pavamani S, Ram TS. Maximum tolerated dose and early response - results of a phase I trial of paclitaxel and cisplatin with radiation therapy in carcinoma of the cervix. Clin Oncol (R Coll Radiol) 2009; 21(6): 488-93.
Tewari KS, Monk BJ. Recent achievements and future developments in advanced and recurrent cervical cancer: trials of the Gynecologic Oncology Group. Semin Oncol 2009; 36(2): 170-80
Haasbeek CJ, Uitterhoeve AL, van der Velden J, Gonzalez DG, Stalpers LJ. Long-term results of salvage radiotherapy for the treatment of recurrent cervical carcinoma after prior surgery. Radiother Oncol 2008 Nov; 89(2): 197-204.
Friedlander M, Grogan M; U.S. Preventative Services Task Force. Guidelines for the treatment of recurrent and metastatic cervical cancer. Oncologist 2002; 7: 342-7.
Dreyer G, Snyman LC, Mouton A, Lindeque BG. Management of recurrent cervical cancer. Best Pract Res Clin Obstet Gynaecol 2005; 19: 631-44.
Wang CJ, Lai CH, Huang HJ, Hong JH, Chou HH, Huang KG, Lin JD. Recurrent cervical carcinoma after primary radical surgery. Am J Obstet Gynecol 1999; 181: 518-24
Randall ME, Evans L, Greven KM, McCunniff AJ, Doline RM. Interstitial reirradiation for recurrent gynecologic malignancies: results and analysis of prognostic factors. Gynecol Oncol 1993 Jan; 48: 23-31.
Jhingran A. Potential advantages of intensity-modulated radiation therapy in gynecologic malignancies. Semin Radiat Oncol 2006; 16: 144-51
Rose PG, Blessing JA, Gershenson DM, et al. Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 1999; 17: 2676-80.
Piver MS, Ghamande SA, Eltabbakh GH, et al. First-line chemotherapy with paclitaxel and platinum for advanced and recurrent cancer of the cervix--a phase II study. Gynecol Oncol 1999; 75: 334-7.
Papadimitriou CA, Sarris K, Moulopoulos LA, et al. Phase II trial of paclitaxel and cisplatin in metastatic and recurrent carcinoma of the uterine cervix. J Clin Oncol 1999; 17: 761-6.
Moore DH, Blessing JA, McQuellon RP, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 2004; 22: 3113-9.
Monk BJ, Sill MW, McMeekin DS, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2009; 27: 4649-55.
Long HJ 3rd, Bundy BN, Grendys EC Jr, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 2005; 23: 4626-33.
Fiorica J, Holloway R, Ndubisi B, et al. Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix. Gynecol Oncol 2002; 85: 89-94
Yun YH, Lee MK, Park SM, Kim YA, Lee WJ, Lee KS, et al. Effect of complementary and alternative medicine on the survival and health-related quality of life among terminally ill cancer patients: a prospective cohort study. Ann Oncol. 2013:24(2);489-94.
Amornrat S, Thitima C, Bandit C. Proportion of Gynecologic Cancer Patients Using Complementary and Alternative Medicine. Asian Pacific Journal of Cancer Prevention. 2009: 10;779-82.
Yoshihiro T, Hitoshi I, Kyousuke O, Shunsuke F, Takashi K, Takaharu K, et al. Can Kampo therapy prolong the life of cancer patient? The Journal of Medical Investigation. 2008:55:99-105
Vincent CC, Xinyin W, Edwin PH, Eric TZ, Bacon FN, Robin SH, et al. Effectiveness of Chinese herbal medicine for cancer palliative care: overview of systematic reviews with meta-analyses. Scientific Reports. 2015: 5:18111
Kim HR, Yoo HS, Beak DG, Park IH, Jang CY, Kim HY, et al. Clinical Practice Guidelines in Korean Medicine for Gastric Cancer. J. Int. Korean Med. 2016:37(1);26-46
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
출판사/학술단체 등이 한시적으로 특별한 프로모션 또는 일정기간 경과 후 접근을 허용하여, 출판사/학술단체 등의 사이트에서 이용 가능한 논문
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.